A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 39, Issue 7, 1996, Pages 1102-1108

  Olsen, Nancy J ^a   Brooks, Raye H ^a   Cush, John J ^b   Lipsky, Peter E ^b   St Clair, E William ^c   Matteson, Eric L ^d   Gold, Kenneth N ^d   Cannon, Grant W ^e   Jackson, Christopher G ^e   McCune, W Joseph ^a   Fox, David A ^a   Teal, Grace ^a   Gruber, James ^a   Espinoza, Luis ⁱ   Caldwell, Jacques ^j   Weisman, Micheal ^k   Lee, Sicy ^l   Abramson, Steven ^l   Calabrese, Leonard ^m   Medsger, Thomas ⁿ   Nelson, Betty ^f,g   Lorenz, Todd ^f,g   Strand, Vibeke ^h   more..

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f CorTherapeutics ^*  (United States)

^g XOMA Corporation   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ LOUISIANA STATE UNIVERSITY   (United States)

^j University of California ^*

^k UNIVERSITY OF CALIFORNIA   (United States)

^l NEW YORK UNIVERSITY   (United States)

^m LERNER RESEARCH INSTITUTE   (United States)

ⁿ UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; METOCLOPRAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD15; PARACETAMOL; PREDNISONE; UNCLASSIFIED DRUG;

ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALAISE; NAUSEA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VOMITING;

ADULT; AGED; ANTIGENS, CD5; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE DEPLETION; MIDDLE AGED; RICIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 8944229691     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390705     Document Type: Article

References (28)

1. Paulus HE, Machleder HI, Levine S, Yu DTY, MacDonald NS: Lymphocyte involvement in rheumatoid arthritis: studies during thoracic duct drainage. Arthritis Rheum 20:1249-1262, 1977
2. Kotzin BL, Stroher S, Engleman EG, Calin A, Hoppe RT, Kansas GS, Terrell CD, Kaplan HS: Treatment of intractable rheumatoid arthritis with total lymphoid irradiation. N Engl J Med 305:969-976, 1981
3. Trentham DE, Beli JA, Anderson RT, Buckley JA, Goetzl EJ, David JR, Austin KF: Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis. N Engl J Med 305:976-982, 1981
4. Townes AS, Sowa JM, Shulman LE: Controlled trial of cyclophosphamide in rheumatoid arthritis: an 18-month double-blind crossover study (abstract). Arthritis Rheum 15:129-130, 1972
5. Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF: Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 30:11-17, 1987
6. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, Olsen NJ, Lee ML, Lorenz TJ, Nelson B, CD5 Plus Rheumatoid Arthritis Investigators Group: Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 36:620-630, 1993
7. Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R, Phillips GL, LeMaistre CF, Gilliland G, Antin JH, Martin P, Tutscha PJ, Trown P, Ackerman SK, O'Reilly RJ, Scannon PJ: Use of anti-pan T-lymphocyte ricin A chain immunotoxin in steroid resistant graft versus host disease. Blood 75:1426-1432, 1990
8. Wacholtz MC, Strand V, Lipsky PE: Treatment of lupus nephritis with CDS plus, an immunoconjugate of anti-CD5 monoclonal antibody and ricin A chain (abstract). Arthritis Rheum 34 (suppl 9):S58, 1991
9. Stafford FJ, Fleisher TA, Lee G, Brown M, Strand V, Austin HA, Balow JE, Klippel JH: A pilot study of anti-CDS ricin A chain immunoconjugate in systemic lupus erythematosus. J Rheumatol 21:2068-2070, 1994
10. Strand V: Clinical trial design and concepts specific for biologic agents in the treatment of rheumatic diseases. In, Monoclonal Antibodies, Cytokines and Arthritis. Edited by T Kresina. New York, Marcel Dekker, 1991
11. Cannon GW, Marble DA, Griffiths MM, Cole BC, McCall S, Schulman SF, Strand V: Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate. J Rheumatol 22:207-213, 1995
12. Fishwild DM, Strand V: Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function. J Rheumatol 21:596-604, 1994
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Finals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988
14. Fishwild D, Staskawicz M, Wu HM, Carroll SF: Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of an added potentiator. Clin Exp Immunol 6:506-513, 1991
15. Cush JJ, Nichols LA, Strand V, Lipsky PE: Treatment of rheumatoid arthritis patients with an anti-CD5 immunoconjugate (abstract). Arthritis Rheum 34(suppl 9)S159, 1991
16. Paulus HE, Egger MJ, Ward JR, Williams HJ, Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33:477-484, 1990
17. Pincus TP, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ: Self-report questionnaire scores in rheumatoid arthritis reflect traditional physical, radiographic and laboratory measures. Ann Intern Med 110:259-266, 1989
18. Efron B: Randomizing and balancing a complicated sequential experiment. In, Biostatistics Casebook. Edited by RG Miller Jr, B Efron, BW Brown Jr, LE Moses. New York, Wiley, 1980
19. Olsen NJ, Teal GP, Strand V: In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis. Clin Immunol Immunopathol 67: 124-129, 1993
20. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38:1097-1106, 1995
21. Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, Weisman MH, Schlegel S, Michaels RM, Luggen ME, Polisson RP, Singer JZ, Kantor SM, Shiroky JB, Small RE, Gomez MI, Reading JC, Egger MJ: A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 31:702-713, 1988
22. Olsen NJ, Brooks RH, Furst D: Variability of immunologic and clinical features in patients with rheumatoid arthritis studied over 24 hours. J Rheumatol 20:940-943, 1993
23. Weinblatt ME, Maier AL, Emery P: Substantial placebo response with parenteral therapy in active rheumatoid arthritis (abstract). Arthritis Rheum 33 (suppl 9):S152, 1990
24. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
25. Dwosh IL, Giles AR, Ford PM, Pater JL, Anastassiades TP, Queen's University Plasmapheresis Study Group: Plasmapheresis therapy in rheumatoid arthritis: a controlled, double-blind, crossover trial. N Engl J Med 308:1124-1129, 1983
26. Wallace D, Goldfinger D, Lower C, Nichols S, Weiner J, Brachman M, Klinenberg JR: A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. N Engl J Med 306:1406-1410, 1982
27. Tilley BC, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JCC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman M, Fowler SE: Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 122:81-89, 1995
28. Turner JA, Deyo RA, Loeser JD, VonKorff M, Fordyce WE: The importance of placebo effects in pain treatment and research. JAMA 271:1609-1614, 1994